Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...
The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug's manufacturer, announced today. This is the second tocilizumab biosimilar ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.
Long-term treatment with tocilizumab was effective in patients with moderate-to-severe thyroid eye disease (TED) that was resistant to corticosteroids, with 58% of patients achieving clinical ...
Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...
Interleukin-6 (IL-6) is a pleiotropic cytokine that may play a role in the regulation of various aspects of the immune response, inflammation, hematopoiesis, and bone metabolism. IL-6 acts by binding ...
Please provide your email address to receive an email when new articles are posted on . The 2017 FDA approval of tocilizumab as the first drug to specifically treat giant cell arteritis ushered in a ...
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results